Menu

FDA Approves Prosthetic Arm

The agency OKs the first prosthetic arm controlled by neural signals from the user’s muscles.

May 14, 2014
Jef Akst

The DEKA armDARPAThe US Food and Drug Administration (FDA) last week (May 9) green-lighted the sale of the DEKA Research and Development Corporation’s prosthetic arm—called “the Luke arm” by its creators—making it the first FDA-approved prosthetic arm with movements controlled by electrical signals sent from the user’s body—either from electrode attached to the muscles in the remaining part of the amputated limb or in the user’s feet. The New Hampshire-based company now seeks a manufacturer to be able to put the DARPA-funded product on the market.

“In comparison to commercially available prosthetics, the new arm offers powered shoulder movements and a wider range of wrist movements,” noted MIT Technology Review, referring to a study published last year. And data examined by the FDA as part of its products fast-track review process demonstrated that “approximately 90 percent of study participants were able to perform activities with the DEKA Arm System that they were not able to perform with their current prosthesis, such as using keys and locks, preparing food, feeding oneself, using zippers, and brushing and combing hair,” according to an agency press release

“Think about our military personnel, who can be great beneficiaries of these devices: before DARPA made an investment in this area the best we could give back to them was metal hooks,” Justin Sanchez, a program manager in DARPA’s new Biological Technologies office, told Bloomberg. “This is a landmark moment for DARPA as an agency.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.